Castle biosciences inc.

Apr 26, 2022 · FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has completed its ... Nov 17, 2023 · Castle Biosciences, Inc. (NASDAQ:CSTL) announced its quarterly earnings results on Sunday, November, 7th. The company reported ($0.47) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by $0.13. The firm earned $23.48 million during the quarter, compared to the consensus estimate of $23.66 million. Castle Biosciences (Nasdaq: CSTL) is a commercial-stage dermatologic cancer company focused on providing physicians and their patients with personalized, clinically actionable genomic information ...Castle Biosciences, Inc. (NASDAQ: CSTL) Castle is a commercial-stage diagnostics company, focused on providing diagnostic and prognostic testing services for dermatological cancers and mental ...

Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to ...

Learn more about the Castle Biosciences Inc. lab opening. bizjournals.com. First look: Castle Biosciences celebrates grand opening of 20,000-square-foot lab in Nova Place. Biotech firm opening new 20,000-square-foot office and lab space in the North Side's Nova Place complex. 4. 5.Castle Biosciences, Inc. (NASDAQ:CSTL) Q2 2023 Earnings Call Transcript Cathie Wood's Top 15 Small-Cap Stock Picks Small Caps Begin to Rebound: 5 Stocks to …

Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma ...Jun 23, 2019 · Our History. Castle Biosciences was founded by Derek Maetzold who believed that traditional methods to determine cancer patients’ prognosis could be improved by newly emerging techniques in molecular biology. We continue to focus on transforming disease management in areas of unmet clinical need through the development and marketing of ... The following unaudited pro forma condensed combined financial information was prepared to give effect to the transaction between Castle Biosciences, Inc. (“Castle” or the “Company”) and Cernostics, Inc., Inc. (“Cernostics”) pursuant to an Agreement and Plan of Merger dated October 18, 2021, as amended (the “Merger Agreement”).9 Nov 2023 ... Castle Biosciences Inc · View all. According to data from the RCT, IDgenetix-guided medication management showed a 37% improvement in response ...Castle Biosciences, Inc. (NASDAQ:CSTL) announced its quarterly earnings results on Sunday, November, 7th. The company reported ($0.47) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by $0.13. The firm earned $23.48 million during the quarter, compared to the consensus estimate of $23.66 million.

Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) ...

Castle’s three-year financial targets include anticipated total revenue of $255-$330 million and anticipated net operating cash flow positivity for the year ending December 31, 2025

Castle Biosciences, Inc. | 10,149 followers on LinkedIn. Improving health through innovative tests that guide patient care | Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company focused on transforming disease management by keeping people first—the patients who benefit from the information that our advanced diagnostic tests …19 Feb 2022 ... Castle Biosciences, Inc., Friendswood, TX 77546, USA. 7 Department of Dermatology, University of Barcelona, IDIBAPS, 08007 Barcelona, Spain ...Currently, Tobin W. Juvenal holds the position of Chief Commercial Officer of Castle Biosciences, Inc. In his past career he held the position of Vice President-Sales for Encysive Pharmaceuticals,...Castle Biosciences, Inc. (the ‘‘Company,’’ “we,” “us” or “our”) was incorporated in the state of Delaware on September 12, 2007. We are a commercial-stage diagnostics company focused on providing physicians and their patients with personalized, clinically actionable information to inform treatment decisions and improve ...FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced data from a study showing ...Operating Status Active. Last Funding Type Post-IPO Equity. Legal Name Castle Biosciences, Inc. Stock Symbol NASDAQ:CSTL. Company Type For Profit. Contact Email [email protected]. Phone Number 602-535-1997. Castle Biosciences is a biotech company that develops and validates diagnostic tests and technologies for the treatment of cancer. 1 Jun 2023 ... NEW YORK – Medicare Administrative Contractor Wisconsin Physicians Service Insurance Corporation has released a proposed local coverage ...

Castle Biosciences, Inc. | 10,098 followers on LinkedIn. Improving health through innovative tests that guide patient care | Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company...C/O CASTLE BIOSCIENCES, INC. 505 S. FRIENDSWOOD DRIVE, SUITE 401 (Street) FRIENDSWOOD: TX: 77546 (City) (State) (Zip) 2. Issuer Name and Ticker or Trading Symbol CASTLE BIOSCIENCES INC [ CSTL] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X: Director:Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes.Castle Biosciences, Inc., Friendswood, Texas. 629 likes · 38 talking about this. Leading diagnostics company improving health through innovative tests that guide patient care. Castle Biosciences, Inc. | Friendswood TX Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ET Company Participants Camilla Zuckero - Vice President, Investor Relations and Corporate Affairs

The Company expects to double its current workforce in Pittsburgh by the end of 2023. May 22, 2023 07:00 AM Eastern Daylight Time. FRIENDSWOOD, Texas-- ( BUSINESS WIRE )--Castle Biosciences, Inc ...Stock analysis for Castle Biosciences Inc (CSTL:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data showing that ...Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to ...Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to ...Castle Biosciences, Inc. | 10,149 followers on LinkedIn. Improving health through innovative tests that guide patient care | Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company focused on transforming disease management by keeping people first—the patients who benefit from the information that our advanced diagnostic tests …29 Jun 2023 ... 1Castle Biosciences, Inc, Friendswood, TX 2Surveillance Research Program, Division of Cancer Control & Population Sciences, National Cancer ...DecisionDx-Melanoma is performed in Castle Biosciences’ CAP accredited, CLIA certified laboratory using formalin-fixed, paraffin embedded (FFPE) primary tumor tissue from either a biopsy or excision. Castle Biosciences is a molecular diagnostics company that provides tumor-specific information for improved treatment decisions and patient ...Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ET Company Participants Camilla Zuckero - Vice President, Investor Relations and Corporate Affairs

Castle Biosciences works with all insurance providers, including Medicare, Medicaid, commercial insurers, and the VA to secure coverage and payment for the DecisionDx-Melanoma test. Castle will submit insurance claims and manage the insurance billing process on behalf of patients. The company also sponsors an industry-leading Patient …

2022 Annual Report April 12, 2023 2022 Annual Report. 2022 Proxy Statement April 21, 2022 2022 Proxy Statement. 2021 Annual Report April 21, 2022 2021 Annual Report. 2021 Proxy Supplement May 13, 2021 2021 Proxy Supplement. 2021 Proxy Statement April 27, 2021 2021 Proxy Statement.

Nov 2, 2023 · Castle Biosciences Reports Third Quarter 2023 Results. Published: Nov 02, 2023. Q3 2023 revenue increased 66% over Q3 2022 to $61 million. Q3 2023 total test reports increased 52% over Q3 2022. Raising full year 2023 revenue guidance to at least $200 million from at least $180 million. Conference call and webcast today at 4:30 p.m. ET. The average Castle Biosciences, Inc. salary ranges from approximately $39,729 per year for Administrative Assistant to $106,781 per year for IT Engineer. Salary information comes from 20 data points collected directly from employees, users, and past and present job advertisements on Indeed in the past 36 months.FRIENDSWOOD, Texas, June 03, 2023--Castle will share new data on DecisionDx®-Melanoma and DecisionDx®-UM during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.An experienced team with deep expertise in discovering, developing, and commercializing diagnostic and prognostic tests. Castle Biosciences offers diagnostic tests that provide actionable, tumor-specific information for improved treatment decisions and patient outcomes.Founder, President and CEO. Derek J. Maetzold founded Castle Biosciences in September 2007 and has served as our President, Chief Executive Officer and as a member of our board of directors since inception. Previously, Mr. Maetzold held leadership roles at Encysive Pharmaceuticals, Schering-Plough Corporation (now Merck), Integrated ...Castle Biosciences. Sales (Current Employee) - Friendswood, TX - March 16, 2021. Castle Biosciences is a very culture & mission driven company that genuinely cares for their employees. Working at Castle for almost 5 years now, I can confidently say that I am a valued employee, who is respected as an individual in a company of 240+ employees.2,091.70 +34.50(+1.68%) Castle Biosciences, Inc. (CSTL) NasdaqGM - NasdaqGM Real Time Price. Currency in USD Follow 2W 10W 9M 19.97 -0.02 (-0.10%) At close: 04:00PM EST 20.35 +0.38 (+1.90%) After...Castle Biosciences Inc (CSTL) USD0.001 ; Trade low · $19.59 ; Year low · $9.26 ; Previous · $0.13 ; Volume · n/a ; Dividend yield · 0.00%.Castle Biosciences, Inc. (CSTL) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.91. This compares to loss of $0.25 per share a year ago.Castle Biosciences, Incorporated is a molecular diagnostics company that develops diagnostic and prognostic assays for rare cancers. Castle's mission is to serve individuals afflicted with rare cancers by offering accurate prognostic tests which provide information for making critical decisions regarding an individual's surveillance and ...

According to the issued ratings of 4 analysts in the last year, the consensus rating for Castle Biosciences stock is Buy based on the current 4 buy ratings for CSTL. The average twelve-month price prediction for Castle Biosciences is $32.29 with a high price target of $41.00 and a low price target of $25.00. Learn more on CSTL's analyst rating ... Castle Biosciences, Inc. , a company improving health through innovative tests that guide patient care, today announced new data showing that DecisionDx-SCC can independently risk-stratify patients...Get the latest Castle Biosciences, Inc. (CSTL) stock news and headlines to help you in your trading and investing decisions.Castle Biosciences, Inc. (NASDAQ: CSTL) Castle is a commercial-stage diagnostics company, focused on providing diagnostic and prognostic testing services for dermatological cancers and mental ...Instagram:https://instagram. mortgage companies tennesseesmall stocksmost promising pot stockspenny stocks pharma Castle Biosciences has not completed the preparation of its financial statements for the fourth quarter or full-year-ended Dec. 31, 2022.The preliminary, unaudited information presented in this press release for the quarter and year-ended Dec. 31, 2022, is based on management’s initial review of the information presented and its current expectations, …Castle Biosciences created a tissue repository to enable all DecisionDx-UM patients to have access to their own tumor tissue for future use. This could include taking advantage of targeted treatments, clinical trials, and further prognostic testing as they become available. Castle Biosciences is a molecular diagnostics company that provides ... nvidia stock buyess tech inc Castle Biosciences announced the acquisition Monday after markets closed. Its shares fell 9 percent to $41.60 in early trading Tuesday on the Nasdaq exchange. Business Latest Technology Biotech ... best day trading stock 13 Apr 2022 ... Castle Bioscience Derek Maetzold expand. Derek Maetzold, president and CEO, Castle Biosciences Inc. Castle Biosciences Inc. Chris Mathews. By ...Castle Biosciences created a tissue repository to enable all DecisionDx-UM patients to have access to their own tumor tissue for future use. This could include taking advantage of targeted treatments, clinical trials, and further prognostic testing as they become available. Castle Biosciences is a molecular diagnostics company that provides ...